You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
NEW YORK – Swiss pharmaceutical company Helsinn on Tuesday said that it has dosed the first patient in a Phase I/II trial of its RET inhibitor TAS0953/HM06 for advanced, RET-altered solid tumors, including non-small cell lung cancer.
...and receive Weekly News bulletins.
Already have a Precision Oncology News or 360Dx or GenomeWeb account?Login Now.
Don't have a Precision Oncology News or 360Dx or GenomeWeb account?Register for Free.